156 related articles for article (PubMed ID: 29867154)
1. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.
De Nunzio C; Brassetti A; Simone G; Lombardo R; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):438-445. PubMed ID: 29867154
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
[TBL] [Abstract][Full Text] [Related]
3. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
[TBL] [Abstract][Full Text] [Related]
4. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
5. Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy.
Morlacco A; Dal Moro F; Rangel LJ; Carlson RE; Schulte PJ; Jeffrey KR
Urol Oncol; 2018 Dec; 36(12):528.e1-528.e6. PubMed ID: 30446466
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract][Full Text] [Related]
7. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
8. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
[TBL] [Abstract][Full Text] [Related]
9. The metabolic syndrome is associated with more aggressive prostate cancer.
Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
[TBL] [Abstract][Full Text] [Related]
10. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.
Bakavičius A; Drevinskaitė M; Daniūnaitė K; Barisienė M; Jarmalaitė S; Jankevičius F
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32033148
[No Abstract] [Full Text] [Related]
12. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
[TBL] [Abstract][Full Text] [Related]
13. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
15. Upgrading and upstaging of low-risk prostate cancer among Korean patients: a multicenter study.
Hwang I; Lim D; Jeong YB; Park SC; Noh JH; Kwon DD; Kang TW
Asian J Androl; 2015; 17(5):811-4. PubMed ID: 25578934
[TBL] [Abstract][Full Text] [Related]
16. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
18. Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy.
Bhindi B; Xie WY; Kulkarni GS; Hamilton RJ; Nesbitt M; Finelli A; Zlotta AR; Evans A; van der Kwast TH; Alibhai SM; Trachtenberg J; Fleshner NE
Urology; 2016 Jul; 93():77-85. PubMed ID: 27015944
[TBL] [Abstract][Full Text] [Related]
19. Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.
Park HJ; Ha YS; Park SY; Kim YT; Lee TY; Kim JH; Lee DH; Kim WJ; Kim IY
Urol Int; 2013; 90(3):301-5. PubMed ID: 23391718
[TBL] [Abstract][Full Text] [Related]
20. Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy.
Alshak MN; Patel N; Gross MD; Margolis D; Hu JC
Urology; 2020 Jan; 135():117-123. PubMed ID: 31568795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
